منابع مشابه
Stroke: 30 years of progress.
In 3 decades, Stroke has evolved from a fledgling publication to the leading journal in the field. Many factors have contributed to this, particularly the succession of outstanding editors in chief. We begin a series on “Stroke: 30 Years of Progress,” wherein each editor recalls the highlights of his tenure, providing a unique view of the past 3 decades (see page 3 for Dr Millikan’s editorial)....
متن کاملAustralian Twin Registry: 30 years of progress.
The Australian Twin Registry (ATR) is a national volunteer resource of twin pairs and higher-order multiples willing to consider participating in health, medical, and scientific research. The vision of the ATR is 'to realize the full potential of research involving twins to improve the health and well-being of all Australians'. The ATR has been funded continuously by the National Health and Med...
متن کاملHIV/AIDS: 30 years of progress and future challenges.
Acquired immune deficiency syndrome (AIDS) was first described 30 years ago in a report from the US Centers for Disease Control. Two years later the causative virus was identified and afterwards named the human immunodeficiency virus (HIV). This article reviews the progress made in the three decades since the recognition of AIDS and the discovery of HIV, with respect to the virus, the infected ...
متن کاملThe next 30 years--will the progress continue?
Spectacular progress has occurred in cardiology during the past 30 years. The major advances that have resulted in the better methods of diagnosis and treatment of patients stem from basic research that was often unrelated to the ultimate practical application. An excellent example of this process is the evolution of the concept of ,B blockade from the pharmacology laboratory to practical clini...
متن کاملCannabinoid physiology and pharmacology: 30 years of progress.
Delta9-Tetrahydrocannabinol from Cannabis sativa is mimicked by cannabimimetic analogs such as CP55940 and WIN55212-2, and antagonized by rimonabant and SR144528, through G-protein-coupled receptors, CB1 in the brain, and CB2 in the immune system. Eicosanoids anandamide and 2-arachidonoylglycerol are the "endocannabinoid" agonists for these receptors. CB1 receptors are abundant in basal ganglia...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: CORROSION ENGINEERING
سال: 1981
ISSN: 0010-9355,1884-1155
DOI: 10.3323/jcorr1974.30.1_13